Cronos Group

Cronos Group

We are a geographically diversified and vertically integrated cannabis group that operates within Health Canada’s Access to Cannabis for Medical Purposes Regulations and distributes globally.
Company Details
Drug Manufacturers - Specialty & Generic
Full time employees

Cronos Group News

1 day ago

Why Investors Shouldn’t Buy Tilray Stock Right Now

Tilray (NASDAQ:TLRY) stock has been one of the few popular cannabis stocks to struggle this year. Tilray stock was thrust into the spotlight when the shares went from $22.50 in August to a 52-week high...

1 day ago

6 Marijuana Stocks With Critical Levels to Watch

In financial markets, there are certain price levels that are more significant than others with regard to the amount of supply and demand that exists at them. In addition, prices are always doing one of...

23 May

Does Cronos Group Look Expensive at the Current Price?

Cronos Group: Analysts' Ratings and Target Price Update(Continued from Prior Part)Cronos GroupCronos Group (CRON) has been trading at a significant premium to the peer average in May—a continuation...

23 May

Cronos Group: Analysts’ Ratings and Target Price

Cronos Group: Analysts' Ratings and Target Price UpdateCronos Group’s ratingsCronos Group (CRON) has experienced an increase in the number of analysts covering the stock. Six analysts covered the stock...

22 May

How Cronos Group and Aurora’s Valuations Compare with Peers

How Do Cannabis Stocks' Valuations Stack Up in May?(Continued from Prior Part)Cronos GroupCronos Group (CRON) saw a big spike in its forward EV-to-EBITDA valuation multiple compared to its historical...

21 May

Cramer Remix: The cannabis stocks I'm eyeing

"The charts, as interpreted by Tim Collins, suggest that GW Pharma and Village Farms are buys here," Jim Cramer says. "I think you should stick with Canopy Growth, and Collins believes that GW Pharma...

21 May

Amyris BioDisrupt 2019 - The Good, The Bad, And The Noise

Last week, I attended the annual investment day, BioDisrupt, at the Amyris ( AMRS ) headquarters in Emeryville. Unless otherwise cited, all of the numbers below are taken from the talks at the event, which...

20 May

Collision Conference 2019

Collision Conference 2019

19 May

How Did Tilray Stack Up to the Competition?

Here's a look at Tilray's recent performance compared with its largest competitors.

19 May

A Top U.S. Pension Loads Up on Alibaba, Cronos, and Zillow Stock, Sells PG&E

The Wisconsin Retirement System, one of only two fully funded state pensions, also slashed its holdings in PG&E, the struggling California utility, last quarter.

Load more

About Cronos Group

Our goal is to establish the most valuable international cannabis community comprised of passionate, daring people, driven by quality and integrity, who are determined to write history, not read about it.
We don’t strive to follow best practices; we aspire to set them by building industry leading companies that transform the perception of cannabis and responsibly elevate the consumer experience.
We never lose sight of our consumer’s trust as a measure of our success, building an iconic portfolio that offers the most enjoyable products on the market while generating value for our shareholders.

Features Cronos Group

Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR.

The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.

Participation in events

$ 15.38
Share volume:
6.324 M
Total value:
135.177 M
Market cap:
5.122 B